New Cancer Treatment Data to Be Presented at ESMO Congress 2026
Eli Lilly will present new clinical data on investigational and established cancer…
mRNA Flu Vaccine Moves Toward Late-Stage Clinical Trial
GSK will advance its mRNA-based seasonal flu vaccine into late-stage trials after…
Repatha Linked to Lower Death Risk in High-Risk Patients Without Previous Heart Attack or Stroke
Amgen reports Phase 3 findings showing Repatha reduced death risk in high-risk…
Personalized mRNA Therapy Shows Positive Phase 3 Results in Melanoma
Merck and Moderna report positive Phase 3 results for their personalized mRNA…
Lacutamab Advances Toward Phase 3 Trial in T-Cell Lymphoma
Sobi and Innate Pharma partner to advance lacutamab into a Phase 3…
New Access Strategy Announced for Investigational Monthly HIV Prevention Pill
Merck has announced an early access strategy for its investigational once-monthly HIV…
Sanofi provides update on MOBILIZE phase 3 study of riliprubart in chronic inflammatory demyelinating polyneuropathy
Sanofi has announced the discontinuation of its Phase 3 MOBILIZE study evaluating…
FDA approves Lilly’s EBGLYSS® for one maintenance dose every eight weeks in patients with moderate-to-severe atopic dermatitis
The U.S. FDA has approved a new maintenance dosing regimen for Eli…
Rigel Pharmaceuticals Signs Global Licensing Deal for VEPPANU™ Breast Cancer Treatment
Rigel Pharmaceuticals has entered an exclusive global licensing agreement with Arvinas and…
GE HealthCare Doses First Patient in Phase 2/3 LUMINA Trial for Manganese-Based MRI Contrast Agent
GE HealthCare has dosed the first patient in its Phase 2/3 LUMINA…
